A Role for Lysophosphatidic Acid and Sphingosine 1-Phosphate in the Pathogenesis of Systemic Sclerosis

被引:0
|
作者
Pattanaik, Debendra
Postlethwaite, Arnold E. [1 ]
机构
[1] Univ Tennessee, Div Connect Tissue Dis, Dept Med, Hlth Sci Ctr, Memphis, TN 38163 USA
关键词
GROWTH-FACTOR-BETA; RHO-KINASE; SCLERODERMA; SPHINGOSINE-1-PHOSPHATE; FIBROBLASTS; RECEPTOR; ACTIVATION; CELLS; INVOLVEMENT; SUPPRESSION;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Systemic sclerosis (SSc) is a complex fibrosing autoimmune disease that has variable clinical manifestations and morbidity/mortality secondary to organ damage due to vasculopathy and/or fibrosis. Initial events in the pathogenesis are manifested by fibroproliferative vasculopathy that compromises delivery of blood to critical organs. There is evidence of autoimmunity early in the disease which persists and is accompanied by fibrotic processes that leave large accumulations of collagen and other matrix components in the intima of blood vessels and extracellularly in the connective tissue of organs affected by the disease. It has recently been realized that the lysophospholipids - lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), which are elevated in sera of SSc patients, are capable of producing many of the abnormalities observed in the vasculature, immune system, and connective tissue of patients with this disease. This article reviews key abnormalities of the vasculature, immune system, and connective tissue in SSc that could be mediated by LPA/S1P. [Discovery Medicine 10(51):161-167, August 2010]
引用
收藏
页码:161 / 167
页数:7
相关论文
共 50 条
  • [21] Involvement of lysophosphatidic acid, sphingosine 1-phosphate and ceramide 1-phosphate in the metabolization of phosphatidic acid by lipid phosphate phosphatases in bovine rod outer segments
    Pasquare, Susana J.
    Salvador, Gabriela A.
    Giusto, Norma Maria
    NEUROCHEMICAL RESEARCH, 2008, 33 (07) : 1205 - 1215
  • [22] Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
    Peyruchaud, Olivier
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (04) : 381 - 391
  • [23] Lysophosphatidic acid and sphingosine 1-phosphate: Two lipid villains provoking cardiovascular diseases?
    Siess, W
    Essler, M
    Brandl, R
    IUBMB LIFE, 2000, 49 (03) : 167 - 171
  • [24] Sphingosine 1-phosphate, but not lysophosphatidic acid, is a potent receptor agonist for human endothelial cells
    Yatomi, Y
    Hisano, N
    Ge, R
    Kazama, F
    Satoh, K
    Ozaki, Y
    THROMBOSIS AND HAEMOSTASIS, 1999, : 347 - 347
  • [25] Regulation of Mammalian Physiology, Development, and Disease by the Sphingosine 1-Phosphate and Lysophosphatidic Acid Receptors
    Blaho, Victoria A.
    Hla, Timothy
    CHEMICAL REVIEWS, 2011, 111 (10) : 6299 - 6320
  • [26] The role of sphingosine 1-phosphate in cancer
    Pyne, Susan
    Ohotski, Jan
    Cochrane, Stuart
    Tonelli, Francesca
    Lim, Keng Gat
    Bittman, Robert
    Edwards, Joanne
    Pyne, Nigel J.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 32 : S33 - S33
  • [27] Differential effects of lysophosphatidic acid (LPA) and sphingosine 1-phosphate (SIP) on signaling of endothelial cells
    Lee, H
    Goetzl, EJ
    FASEB JOURNAL, 2001, 15 (04): : A111 - A111
  • [28] Signal Transduction Responses to Lysophosphatidic Acid and Sphingosine 1-Phosphate in Human Prostate Cancer Cells
    Gibbs, Terra C.
    Rubio, Maria V.
    Zhang, Zhihong
    Xie, Yuhuan
    Kipp, Kevin R.
    Meier, Kathryn E.
    PROSTATE, 2009, 69 (14): : 1493 - 1506
  • [29] Roles for CCN proteins in Lysophosphatidic Acid and Sphingosine 1-Phosphate Signaling in Prostate Cancer Cells
    Balijepalli, Pravita
    Knode, Brianna K.
    Nahulu, Samuel A.
    Meier, Kathryn E.
    FASEB JOURNAL, 2022, 36
  • [30] Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate
    Goetzl, EJ
    An, SZ
    FASEB JOURNAL, 1998, 12 (15): : 1589 - 1598